Lyra Therapeutics Inc.’s $100.5 million private placement has investors moving to the tune of the ear, nose and throat specialty therapeutics company. Lyra’s stock (NASDAQ:LYRA) jumped from early April trading in the $4.20 range to $6.02 with the announcement April 8 of the pending placement. The stock shot up again on April 13 when the placement finalized and surged in after-hours trading, ultimately spiking over $7 shortly after the opening bell April 14.
Versant Ventures is committing $50 million in series A funding to Cimeio Therapeutics Inc., which aims to bring new possibilities in terms of disease targeting and safety to bear on a wide range of cell therapy applications, including hematopoietic stem cell transplantation (HSCT) and adoptive cell transfer.
CDR-Life Inc. has closed a $76 million series A round to advance development of a new generation of cancer immunotherapies designed to treat solid tumors by targeting intracellular antigens that occur only in tumors, with the aim of increasing effectiveness while reducing off-target effects.
Biopharmas raising money in public or private financings, including: Affimed, Aquestive, Blue Water, Crinetics, Liquidia, Lixte, Lyra, Navidea and NLS.
RSS
